Abstract Body

Strategies to control Mycobacterium tuberculosis (Mtb) drug resistance include universal access to quality-controlled drug resistance (DR) testing coupled with aligned treatment regimens and patient centred treatment support. We examined the impact of drug resistance mutations (DRM) on mortality in HIV+ and HIV- patients with TB in eight high-burden countries.

We included 247 HIV+ and 335 HIV- adult patients diagnosed with TB in Kenya, South Africa, Democratic Republic of the Congo, Nigeria, Côte d’Ivoire, Peru and Thailand; 60 patients died during treatment. Sampling was stratified by HIV status and on-site DR diagnosis, as determined by locally available tests (Xpert/LPA and/or culture). Whole genome sequences (WGS) were scanned for high-confidence DRM. We compared the DR profiles diagnosed at sites with the DRM from WGS to identify the most common mutations and the DR missed locally. We used logistic regression to examine their association with mortality during TB treatment, adjusted for sex, age and HIV status. We ran a separate model for each DRM with frequency >20 and for combined groups of rare DRM. The reference group consisted of TB patients with pan-susceptible Mtb based on WGS.

The most common mutations in our sample were S315T, S450L, L79S, C-15T, M306V, D435V, M306I and K43R (details in Table 1). While DR to rifampicin (RIF) was missed only in 2% of cases, DR to isoniazid (INH) was missed in 25% of cases and for all other drugs in >70% cases. The DRM individually associated with the largest increase in mortality were S315T with OR 3.7 (95%CI: 2.2-6.5), D453V with OR 3.8 (95%CI: 1.7-8.4) and L79S with OR 4.13 (95%CI: 2-8.5). The OR for groups of rare DRM conferring resistance to RIF, ethambutol (EMB) and all second-line drugs were also statistically significant, ranging from 2.9 to 4.5. Results were similar in HIV+ and HIV- patients.

We identified several DRM associated with increased mortality in TB patients from eight high-burden countries. Many of the conferred DR were missed by local DR tests, potentially leading to an inadequate treatment. Our results highlight the critical need of rapid molecular point-of-care DR tests that cover a broader range of DRM and thus could contribute to more effective treatment and reduced mortality among patients with MDR TB.